On topical timolol gel-forming solution for infantile hemangiomas

Pediatric Dermatology

Volumn 30, Issue 1, 2013, Pages 160-161

  Berk, David R ^a   Lehman, Paul A ^b   Franz, Thomas J ^b   Blunt, Jeffrey R ^c   Bayliss, Susan J ^a  

^a WASHINGTON UNIVERSITY   (United States)

^b Cetero Research   (United States)

^c BARNES JEWISH HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

MACROGOL; MINERAL OIL; PROPRANOLOL; TIMOLOL;

ABSENCE OF SIDE EFFECTS; CAPILLARY HEMANGIOMA; DRUG ABSORPTION; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; EPIDERMIS; GEL; HEART RATE; HUMAN; LETTER; PRIORITY JOURNAL; STRATUM CORNEUM; SYSTEMIC THERAPY; TRANSDERMAL PATCH;

ADRENERGIC BETA-ANTAGONISTS; HEMANGIOMA; HUMANS; SKIN NEOPLASMS; TIMOLOL;

EID: 84872304180     PISSN: 07368046     EISSN: 15251470     Source Type: Journal    
DOI: 10.1111/pde.12060     Document Type: Letter

References (12)

1. McMahon P, Oza V, Frieden IJ,. Topical timolol for infantile hemangiomas: putting a note of caution in "cautiously optimistic." Pediatr Dermatol 2012; 29: 127-130.
2. Korte JM, Kaila T, Saari KM,. Systemic bioavailability and cardiopulmonary effects of 0.5% timolol eyedrops. Graefes Arch Clin Exp Ophthalmol 2002; 240: 430-445.
3. Vlasses PH, Ribeiro LG, Rotmensch HH, et al. Initial evaluation of transdermal timolol: serum concentrations and beta-blockade. J Cardiovasc Pharmacol 1985; 7: 245-250.
4. Bergstrom KG, Strober BE,. Principles of topical therapy. In:, Wolff K, Goldsmith LA, Katz SI, et al, eds. Fitzpatrick's Dermatology in General Medicine, 7th ed. New York: McGraw-Hill, 2008.
5. Buxton IL, Benet LZ,. Pharmacokinetics: the dynamics of drug absorption, distribution, metabolism, and elimination. In:, Brunton LL, Chabner BA, Knollmann BC, eds. Goodman & Gilman's the Pharmacological Basis of Therapeutics, 12th ed. New York: McGraw-Hill, 2011.
6. Chakkittakandiyil A, Phillips R, Frieden IJ, et al. Timolol maleate 0.5% or 0.1% gel-forming solution for infantile hemangiomas: a retrospective, multicenter, cohort study. Pediatr Dermatol 2012; 29: 28-31.
7. Oranje AP, Janmohamed SR, Madern GC, et al. Treatment of small superficial haemangioma with timolol 0.5% ophthalmic solution: a series of 20 cases. Dermatology 2011; 223: 330-334.
8. Blatt J, Morrell DS, Buck S, et al. β-blockers for infantile hemangiomas: a single-institution experience. Clin Pediatr (Phila) 2011; 50: 757-763.
9. Chambers CB, Katowitz WR, Katowitz JA, et al. A controlled study of topical 0.25% timolol maleate gel for the treatment of cutaneous infantile capillary hemangiomas. Ophthal Plast Reconstr Surg 2012; 28: 103-106.
10. Ni N, Langer P, Wagner R, et al. Topical timolol for periocular hemangioma: report of further study. Arch Ophthalmol 2011; 129: 377-379.
11. Pope E, Chakkittakandiyil A,. Topical timolol gel for infantile hemangiomas: a pilot study. Arch Dermatol 2010; 146: 564-565.
12. Moehrle M, Leaute-Labreze C, Schmidt V, et al. Topical timolol for small hemangiomas of infancy. Pediatr Dermatol 2012; Apr 4. doi: 10.1111/j.1525-1470. 2012.01723.x [Epub ahead of print].